Arena Pharmaceuticals, Inc.’s (ARNA) share price has entered into oversold territory with an RSI value of 28.73. The Zacks Consensus Estimate on Arena Pharmaceuticals, Inc.’s earnings for the full year period has loss by 0.01 cents over the past two months to $-0.14 per share. Currently, Arena Pharmaceuticals, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (ARNA) after its recent drop.


ARENA PHARMACEUTICALS INC (ARNA): Free Stock Analysis Report


Zacks Investment Research